文献速递药疹与重症皮肤不良反应皮肤肿瘤

抗癌治疗与光敏性

Anticancer treatments and photosensitivity.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-01-01

本文综述了传统化疗药、靶向抗癌药和免疫检查点抑制剂相关的光敏性,涵盖光毒性和光变态反应、紫外线回忆反应、与治疗相关白癜风伴 exaggerated 晒伤反应、药物诱导性皮肤狼疮及紫外线诱导性色素沉着。文章还讨论了新一代靶向药和免疫检查点抑制剂近期报告的光敏反应,强调持续监测致光敏药物及教育患者采取预防性 UVA/UVB 光防护措施的重要性。

要点

  • 抗癌治疗相关光敏性可导致剂量调整甚至中断治疗,严重影响生活质量。
  • 诊断挑战在于反应异质性及常合并使用其他潜在致光敏药物。
  • 需持续监测致光敏药物并教育患者采取预防性 UVA/UVB 光防护。

核心结论

  • 抗癌治疗相关光敏性表现多样,包括光毒性、光变态反应、紫外线回忆反应、与治疗相关白癜风伴 exaggerated 晒伤反应、药物诱导性皮肤狼疮和紫外线诱导性色素沉着。
  • 新一代靶向抗癌治疗和免疫检查点抑制剂近期也有光敏反应报告。
  • 持续监测致光敏药物并教育患者采取预防性 UVA/UVB 光防护措施很重要。

研究设计与样本

  • 综述,旨在描述接受抗癌治疗患者中最具特征性的光敏性表现。

主要发现

  • 光敏反应可严重影响癌症患者健康和生活质量,严重时导致剂量调整或中断/停止抗癌治疗。
  • 光敏反应异质性及合并使用其他潜在致光敏药物(抗生素、伏立康唑、非甾体抗炎药等)使诊断和预防具有挑战性。
  • 综述描述了光毒性和光变态反应及其他潜在光诱导表现,包括紫外线回忆反应、与治疗相关白癜风伴 exaggerated 晒伤反应、药物诱导性皮肤狼疮红斑和紫外线诱导性色素沉着。
  • 讨论了新一代靶向抗癌治疗和免疫检查点抑制剂近期报告的光敏反应。

临床怎么用

  • 强调持续监测以识别致光敏药物的重要性。
  • 强调教育患者采取预防性 UVA/UVB 光防护措施的必要性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-induced photosensitivity is associated with a wide range of anticancer treatments, including conventional chemotherapeutic agents, targeted anticancer therapies, and immune checkpoint inhibitors. These dermatologic adverse events can have a major impact on the well-being and quality of life of cancer patients, leading to dose modifications and interruption or discontinuation of anticancer treatments in severe cases. However, the heterogeneous nature of the photosensitive reactions induced by these agents, as well as the common concomitant use of other potentially photosensitizing drugs (antibiotics, voriconazole, nonsteroidal anti-inflammatory drugs, etc.), can make the diagnosis and, therefore the prevention, of these adverse events particularly challenging. The aim of this review is to describe the most characteristic forms of photosensitivity observed in patients being treated with anticancer treatments, including phototoxicity and photoallergy, and other potentially photo-induced manifestations such as UV recall, exaggerated sunburn reactions associated with treatment-related vitiligo, drug-induced cutaneous lupus erythematosus, and UV-induced hyperpigmentation. We also discuss the photosensitive reactions recently reported with new-generation targeted anticancer therapies and immune checkpoint inhibitors and highlight the importance of continued surveillance to identify photosensitizing agents, and of educating patients on the need for preventive UVA/UVB photoprotective measures.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Sibaud V. Anticancer treatments and photosensitivity. J Eur Acad Dermatol Venereol. 2022. PMID: 35738806. doi:10.1111/jdv.18200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。